Sex steroid-induced changes in circulating monocyte chemoattractant protein-1 levels may contribute to metabolic dysfunction in obese men

Journal of Clinical Endocrinology and Metabolism

Volumn 97, Issue 7, 2012, Pages

  Ruige, Johannes B ^a   Bekaert, Marlies ^a   Lapauw, Bruno ^a   Fiers, Tom ^a   Lehr, Stefan ^b   Hartwig, Sonja ^b   De Wiza, Daniella Herzfeld ^b   Schiller, Martina ^b   Passlack, Waltraud ^b   Van Nieuwenhove, Yves ^a   Pattyn, Piet ^a   Cuvelier, Claude ^a   Taes, Youri E ^a   Sell, Henrike ^b   Eckel, Juergen ^b   Kaufman, Jean Marc ^a   Ouwens, D Margriet ^b  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b LEIBNIZ CENTER FOR DIABETES RESEARCH AT HEINRICH HEINE UNIVERSITY DÜSSELDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; AROMATASE INHIBITOR; CYTOKINE; ESTRADIOL; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 5; INTERLEUKIN 6; LEPTIN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; SEX HORMONE; TESTOSTERONE;

ADIPOCYTE; ARTICLE; CELL SIZE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; ESTRADIOL BLOOD LEVEL; HUMAN; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MORBID OBESITY; OBESITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TESTOSTERONE BLOOD LEVEL;

ADIPOKINES; ADULT; CASE-CONTROL STUDIES; CHEMOKINE CCL2; COMORBIDITY; CROSS-SECTIONAL STUDIES; GONADAL STEROID HORMONES; HUMANS; MALE; METABOLIC DISEASES; MIDDLE AGED; OBESITY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SEX FACTORS; YOUNG ADULT;

EID: 84863558850     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2011-3069     Document Type: Article

References (20)

1. Grossmann M, Gianatti EJ, Zajac JD 2010 Testosterone and type 2 diabetes. Curr Opin Endocrinol Diabetes Obes 17:247-256
2. Wang C, Jackson G, Jones TH, Matsumoto AM, Nehra A, Perelman MA, Swerdloff RS, Traish A, Zitzmann M, Cunningham G 2011 Low testosterone associated with obesity and the metabolic syndrome contributes to sexual dysfunction and cardiovascular disease risk in men with type 2 diabetes. Diabetes Care 34:1669-1675
3. Zitzmann M 2009 Testosterone deficiency, insulin resistance and the metabolic syndrome. Nat Rev Endocrinol 5:673-681
4. Williams G 2012 Aromatase up-regulation, insulin and raised intracellular oestrogens in men induce adiposity, metabolic syndrome and prostate disease, via aberrant ER-α and GPER signalling. Mol Cell Endocrinol 351:269-278
5. Laaksonen DE, Niskanen L, Punnonen K, Nyyssönen K, Tuomainen TP, Valkonen VP, Salonen JT 2005 The metabolic syndrome and smoking in relation to hypogonadism in middle-aged men: a prospective cohort study. J Clin Endocrinol Metab 90:712-719 (Pubitemid 40279184)
6. Haring R, Völzke H, Felix SB, Schipf S, Dörr M, Rosskopf D, Nauck M, Schöfl C, Wallaschofski H 2009 Prediction of metabolic syndrome by low serum testosterone levels in men: results from the study of health in Pomerania. Diabetes 58:2027-2031
7. Stellato RK, Feldman HA, Hamdy O, Horton ES, McKinlay JB 2000 Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men: prospective results from the Massachusetts Male Aging Study. Diabetes Care 23:490-494 (Pubitemid 30185792)
8. Lapauw B, Ouwens M, 't Hart LM, Wuyts B, Holst JJ, T'Sjoen G, Kaufman JM, Ruige JB 2010 Sex steroids affect triglyceride handling, glucose-dependent insulinotropic polypeptide, and insulin sensitivity: a 1-week randomized clinical trial in healthy young men. Diabetes Care 33:1831-1833
9. De Pergola G 2000 The adipose tissue metabolism: role of testosterone and dehydroepiandrosterone. Int J Obes Relat Metab Disord 24(Suppl 2):S59-S63 (Pubitemid 30461950)
10. Pallottini V, Bulzomi P, Galluzzo P, Martini C, Marino M 2008 Estrogen regulation of adipose tissue functions: involvement of estrogen receptor isoforms. Infect Disord Drug Targets 8:52-60 (Pubitemid 351688295)
11. Sell H, Eckel J 2009 Chemotactic cytokines, obesity and type 2 diabetes: in vivo and in vitro evidence for a possible causal correlation? Proc Nutr Soc 68:378-384
12. Dhindsa S, Furlanetto R, Vora M, Ghanim H, Chaudhuri A, Dandona P 2011 Low estradiol concentrations in men with subnormal testosterone concentrations and type 2 diabetes. Diabetes Care 34:1854-1859
13. Giagulli VA, Kaufman JM, Vermeulen A 1994 Pathogenesis of the decreased androgen levels in obese men. J Clin Endocrinol Metab 79:997-1000 (Pubitemid 24342237)
14. Jensen TK, Andersson AM, Jørgensen N, Andersen AG, Carlsen E, Petersen JH, Skakkebaek NE 2004 Body mass index in relation to semen quality and reproductive hormones among 1,558 Danish men. Fertil Steril 82:863-870 (Pubitemid 39346431)
15. Kalinchenko SY, Tishova YA, Mskhalaya GJ, Gooren LJ, Giltay EJ, Saad F 2010 Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double-blinded placebo-controlled Moscow study. Clin Endocrinol (Oxf) 73:602-612
16. Bengtsson AK, Ryan EJ, Giordano D, Magaletti DM, Clark EA 2004 17β-Estradiol (E2) modulates cytokine and chemokine expression in human monocyte-derived dendritic cells. Blood 104:1404-1410 (Pubitemid 39166518)
17. Murphy HS, Sun Q, Murphy BA, Mo R, Huo J, Chen J, Chensue SW, Adams M, Richardson BC, Yung R 2004 Tissue-specific effect of estradiol on endothelial cell-dependent lymphocyte recruitment. Microvasc Res 68:273-285 (Pubitemid 40288124)
18. Nebel D, Jönsson D, Norderyd O, Bratthall G, Nilsson BO 2010 Differential regulation of chemokine expression by estrogen in human periodontal ligament cells. J Periodontal Res 45:796-802
19. Herder C, Baumert J, Thorand B, Koenig W, de Jager W, Meisinger C, Illig T, Martin S, Kolb H 2006 Chemokines as risk factors for type 2 diabetes: results from the MONICA/KORA Augsburg study, 1984-2002. Diabetologia 49:921-929
20. Oh DY, Morinaga H, Talukdar S, Bae EJ, Olefsky JM 2012 Increased macrophage migration into adipose tissue in obese mice. Diabetes 61:346-354